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Abstract
Joint models for longitudinal and survival data have gained a lot of attention in recent years, with
the development of myriad extensions to the basic model, including those which allow for multivariate
longitudinal data, competing risks and recurrent events. Several software packages are now also available
for their implementation. Although mathematically straightforward, the inclusion of multiple longitudi-
nal outcomes in the joint model remains computationally difficult due to the large number of random
effects required, which hampers the practical application of this extension. We present a novel approach
that enables the fitting of such models with more realistic computational times. The idea behind the
approach is to split the estimation of the joint model in two steps; estimating a multivariate mixed model
for the longitudinal outcomes, and then using the output from this model to fit the survival submodel.
So called two-stage approaches have previously been proposed, and shown to be biased. Our approach
differs from the standard version, in that we additionally propose the application of a correction factor,
adjusting the estimates obtained such that they more closely resemble those we would expect to find with
the multivariate joint model. This correction is based on importance sampling ideas. Simulation studies
show that this corrected-two-stage approach works satisfactorily, eliminating the bias while maintaining
substantial improvement in computational time, even in more difficult settings.
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1 Introduction
Joint models for longitudinal and survival data have become a valuable asset in the toolbox of modern
data scientists. After the seminal papers of Faucett and Thomas [1996] and Wulfsohn and Tsiatis [1997],
several extensions of these models have been proposed in the literature. These include, amongst oth-
ers, flexible specification of the longitudinal model [Brown et al., 2005a], consideration of competing risks
[Elashoff et al., 2008, Andrinopoulou et al., 2014] and multi-state models [Ferrer et al., 2016], and the cal-
culation of dynamic predictions [Proust-Lima and Taylor, 2009, Rizopoulos, 2011, Rizopoulos et al., 2014,
Andrinopoulou and Rizopoulos, 2016, Rizopoulos et al., 2017, Andrinopoulou et al., 2018]. A particularly
useful and practical extension is that which allows for the inclusion of multiple longitudinal outcomes
[Rizopoulos and Ghosh, 2011a, Chi and Ibrahim, 2006, Brown et al., 2005b, Lin et al., 2002]. In medical
settings in particular, data collection is likely to be complex: while the standard joint model allows us to
determine the association between a survival outcome and a single longitudinal outcome (biomarker), there
are more often than not multiple biomarkers relevant to the event of interest. Extending the univariate joint
model to accommodate these multiple longitudinal outcomes allows us to incorporate more information,
improving prognostication and enabling us to better make sense of the complex underlying nature of the
disease dynamics. A motivating example of this is the Bio-SHiFT cohort study; a prospective observational
study conducted in the Netherlands on chronic heart failure (CHF) patients. The primary focus of the
study was to determine whether or not disease progression in individual CHF patients can be assessed using
longitudinal measurements of several blood biomarkers [van Boven et al., 2018]. Previous work on this data
has focused mainly on the association between each individual biomarker and a single composite event, but
it is likely that the predictive value of the biomarkers will be more accurately determined when they are
assessed in concert.
Extension to the multivariate case is mathematically straightforward, and may be easily combined with
other extensions, allowing for longitudinal outcomes of varying types; left, right and interval censoring; and
the inclusion of competing risks, amongst others. There are also now a number of excellent software packages
available, which make for easier implementation of the more complex models. There are however technical
challenges which hamper the widespread use of these models. As the number of longitudinal outcomes
increases, and thus the number of random effects, standard methods become computationally prohibitive:
under a Bayesian approach, the number of parameters to sample becomes unreasonably large, and in the case
of maximum likelihood, we are required to numerically approximate the integrals over the random effects,
which is challenging in high dimensions. The practical solution most commonly used in such settings is that
of the two-stage approach, wherein a multivariate mixed model is first used for the longitudinal outcomes,
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following which, the output of this model is used to fit a survival submodel. Unfortunately, substantial
research on this topic indicates that this approach results in biased estimates [Tsiatis and Davidian, 2004,
Rizopoulos, 2012, Ye et al., 2008]. In this paper, we propose an adaptation of the simple two-stage approach
which eliminates the bias and substantially reduces computational time. We propose the use of a correction
factor, based on importance sampling theory [Press et al., 2007, Section 7.9]. This correction factor allows
us to re-weight each realization of the MCMC sample obtained from the Bayesian estimation of the two-
stage approach, such that the resulting estimates more closely approximate those obtained via the full
multivariate joint model. The weights are given by the target distribution (the full posterior distribution of
the multivariate joint model), divided by the product of the posterior distributions for each of the two stages,
evaluated for each iteration of the MCMC sample. The use of this correction factor alone is not enough
to eliminate the bias, but, prior to its application, the two-stage approach is itself modified: where before,
in the second stage, only the parameters of the survival submodel were updated, we now also update the
random effects. These adaptations combined, achieve unbiased estimates in a fraction of the time required
to compute the full multivariate model.
The rest of the paper is organised as follows: Section 2 introduces the full multivariate joint model,
and Section 3 discusses the estimation of the model under the Bayesian paradigm. Section 4 introduces
the importance-sampling corrected two-stage approach, and presents the results of a simple simulation, and
Section 5 the importance-sampling corrected two-stage approach with updated random effects. Section 6
presents the results of a more complex simulation, and finally in Section 7 we look at an analysis of the
Bio-SHiFT data.
2 Joint Model Specification
We start with a general definition of the framework of multivariate joint models for multiple longitudinal
outcomes and an event time.
Let Dn = {Ti, T
U
i , δi,yi; i = 1, . . . , n} denote a sample from the target population, where T
∗
i denotes the
true event time for the i-th subject, Ti and T
U
i the observed event times. Then δi ∈ {0, 1, 2, 3} denotes the
event indicator, with 0 corresponding to right censoring (T ∗i > Ti), 1 to a true event (T
∗
i = Ti), 2 to left
censoring (T ∗i < Ti), and 3 to interval censoring (Ti < T
∗
i < T
U
i ). Assuming K longitudinal outcomes we let
yki denote the nki×1 longitudinal response vector for the k-th outcome (k = 1, . . . ,K) and the i-th subject,
with elements ykij denoting the value of the k-th longitudinal outcome for the i-th subject, taken at time
point tkij , j = 1, . . . , nki.
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To accommodate multivariate longitudinal responses of different types in a unified framework, we postu-
late a generalized linear mixed effects model. In particular, the conditional distribution of yki given a vector
of random effects bki is assumed to be a member of the exponential family, with linear predictor given by
gk
[
E{yki(t) | bki}
]
= ηki(t) = x
⊤
ki(t)βk + z
⊤
ki(t)bki (1)
where gk(·) denotes a known one-to-one monotonic link function, yki(t) denotes the value of the k-th lon-
gitudinal outcome for the i-th subject at time point t, and xki(t) and zki(t) denote the design vectors for
the fixed-effects βk and the random effects bki, respectively. The dimensionality and composition of these
design vectors is allowed to differ between the multiple outcomes, and they may also contain a combination
of baseline and time-varying covariates. To account for the association between the multiple longitudinal
outcomes we link their corresponding random effects. More specifically, the complete vector of random ef-
fects bi = (b
⊤
1i, b
⊤
2i, . . . , b
⊤
Ki)
⊤ is assumed to follow a multivariate normal distribution with mean zero and
variance-covariance matrix D.
For the survival process, we assume that the risk for an event depends on a function of the subject-specific
linear predictor ηi(t) and/or the random effects. More specifically, we have
hi(t | Hi(t),wi(t)) =
lim
∆t→0
Pr{t ≤ T ∗i < t+∆t | T
∗
i ≥ t,Hi(t),wi(t)}
∆t
, t > 0
= h0(t) exp
[
γ
⊤
wi(t) +
K∑
k=1
Lk∑
l=1
fkl{Hki(t),wi(t),bki,αkl}
]
, (2)
where Hki(t) = {ηki(s), 0 ≤ s < t} denotes the history of the underlying longitudinal process up to t, h0(·)
denotes the baseline hazard function, and wi(t) is a vector of exogenous, possibly time-varying, covariates
with corresponding regression coefficients γ. Functions fkl(·), parameterized by vector αkl, specify which
components/features of each longitudinal outcome are included in the linear predictor of the relative risk
model Brown [2009], Rizopoulos and Ghosh [2011b], Rizopoulos [2012], Rizopoulos et al. [2014]. Some ex-
amples, motivated by the literature, are (subscripts kl have been dropped in the following expressions but
are assumed):
f{Hi(t),wi(t), bi,α} = αηi(t),
f{Hi(t),wi(t), bi,α} = α1ηi(t) + α2η
′
i(t), η
′
i(t) =
dηi(t)
dt
,
f{Hi(t),wi(t), bi,α} = α
∫ t
0
ηi(s) ds.
These formulations of f(·) postulate that the hazard of an event at time t may be associated with the
underlying level of the biomarker at the same time point, the slope of the longitudinal profile at t or the
accumulated longitudinal process up to t. In addition, the specified terms from the longitudinal outcomes
may also interact with some covariates in the wi(t). Furthermore, note, that we allow a combination of Lk
functional forms per longitudinal outcome. Finally, the baseline hazard function h0(·) is modeled flexibly
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using a B-splines approach, i.e.,
log h0(t) =
Q∑
q=1
γh0,qBq(t,v), (3)
where Bq(t,v) denotes the q-th basis function of a B-spline with knots v1, . . . , vQ and γh0 the vector of spline
coefficients; typically Q = 15 or 20.
3 Likelihood and Priors
As explained in Section 1, we use a Bayesian approach for the estimation of the joint model’s parameters.
The posterior distribution of the model parameters given the observed data is derived under the assumptions
that given the random effects, the longitudinal outcomes are independent from the event times, the multiple
longitudinal outcomes are independent of each other, and the longitudinal responses of each subject in each
outcome are independent. Under these assumptions the posterior distribution is analogous to:
p(θ, b) ∝
n∏
i=1
K∏
k=1
nki∏
j=1
p(ykij | bki,θ) p(Ti, T
U
i , δi | bki,θ) p(bki | θ) p(θ), (4)
where θ denotes the full parameter vector, and
p(ykij | θ, bki) = exp
{[ykijψkij(bki)− ck{ψkij(bki)}]
ak(ϕ)− dk(ykij , ϕ)
}
,
with ψkij(bki) and ϕ denoting the natural and dispersion parameters in the exponential family, respectively,
and ck(·), ak(·), and dk(·) are known functions specifying the member of the exponential family. For the
survival part accordingly we have
p(Ti, T
U
i , δi | bi,θ) =
{
hi(Ti | Hi(Ti),wi(Ti))
}I(δi=1)
× exp
{
−
∫ Ti
0
hi(s | Hi(s),wi(s)) ds
}I(δi∈{0,1})
×
{
1− exp
{
−
∫ Ti
0
hi(s | Hi(s),wi(s)) ds
}}I(δi=2)
×
{
exp
{
−
∫ Ti
0
hi(s | Hi(s),wi(s)) ds
}
− exp
{
−
∫ TU
i
0
hi(s | Hi(s),wi(s)) ds
}}I(δi=3)
, (5)
where I(·) denotes the indicator function. The integral in the definition of the cumulative hazard function
does not have a closed-form solution, and thus a numerical method is employed for its evaluation. Standard
options are the Gauss-Kronrod and Gauss-Legendre quadrature rules.
For the parameters of the longitudinal outcomes we use standard default priors. More specifically,
independent normal priors with zero mean and variance 1000 for the fixed effects and half-Student’s t priors
with 3 degrees of freedom for scale parameters. The covariance matrix of the random effects is parameterized
in terms of a correlation matrix Ω and a vector of σd. For the correlation matrix Ω we use the LKJ-
Correlation prior proposed by Lewandowski et al. [2009] with parameter ζ = 1.5. For each element of σd
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we use a half-Student’s t prior with 3 degrees of freedom. For the regression coefficients γ of the relative
risk model we assume independent normal priors with zero mean and variance 1000. The same prior is
also assumed for the vector of association parameters α. However, when α becomes high dimensional (e.g.,
when several functional forms are considered per longitudinal outcome), we opt for a global-local ridge-type
shrinkage prior. More specifically, for the s-th element of α we assume
αs ∼ N (0, τψs),
τ−1 ∼ Gamma(0.1, 0.1),
ψ−1s ∼ Gamma(1, 0.01).
The global smoothing parameter τ has sufficient mass near zero to ensure shrinkage, while the local smoothing
parameter ψs allows individual coefficients to attain large values. The motivation for using this type of prior
distribution in this case is that we expect the different terms behind the specification of f(·) to be correlated,
and many of the corresponding coefficients to be non-zero. Nonetheless, other options of shrinkage or variable-
selection priors could also be used Andrinopoulou and Rizopoulos [2016]. Finally, the penalized version of
the B-spline approximation to the baseline hazard is specified using the following hierarchical prior for γh0
Lang and Brezger [2004]:
p(γh0 | τh) ∝ τ
ρ(K)/2
h exp
(
−
τh
2
γ
⊤
h0
Kγh0
)
,
where τh is the smoothing parameter that takes a
Gamma(1, τhδ) prior distribution, with a hyper-prior τhδ ∼ Gamma(10
−3, 10−3), which ensures a proper
posterior distribution for γh0 Jullion and Lambert [2007], K = ∆
⊤
r ∆r + 10
−6I, with ∆r denoting the r-th
difference penalty matrix, and where ρ(K) denotes the rank of K.
4 Corrected Two-Stage Approach
4.1 Importance sampling correction
Carrying out a full Bayesian estimation of the multivariate joint model is straightforward, using either Markov
chain Monte Carlo (MCMC) or Hamiltonian Monte Carlo (HMC). However, this estimation becomes very
challenging from a computational viewpoint, due to the high number of random effects involved, and the
requirement for numerical integration in the calculation of the density of the survival outcome (5). This
limitation has hampered the use of multivariate joint models in practice.
The two-stage approach, which entails fitting the longitudinal and survival outcomes separately, is the
solution most often used to overcome this computational deadlock. Using this approach, under the Bayesian
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framework, we would have the following two stages:
S-I: We fit a multivariate mixed model for the longitudinal outcomes using either MCMC or HMC, and we
obtain a sample {θ(m)y , b
(m);m = 1, . . . ,M} of size M from the posterior,
p(θy, b | y) ∝
n∏
i=1
K∏
k=1
nki∏
j=1
p(ykij | bki,θ) p(bki | θ) p(θy),
where θy denotes the subset of the parameters that are included in the definition of the longitudinal sub-
models (including the parameters in the random-effects distribution).
S-II: Utilizing the sample from Stage I, we obtain a sample for the parameters of the survival submodel
{θ
(m)
t ;m = 1, . . . ,M} from the corresponding posterior distribution,
p(θt | T˜ , δ,θ
(m)
y , b
(m)) ∝
n∏
i=1
p(T˜i, δi | θt, b
(m)
i , θ
(m)
y ) p(θt),
where θt denotes the subset of the parameters that are included in the definition of the survival submodel,
and T˜ = (T, TU).
This two-stage procedure essentially entails the same number of iterations as the full Bayesian estimation
of the multivariate joint model. The computational benefits stem from the fact that we do not need to
numerically integrate the survival submodel density function in Stage I. Even though this approach greatly
reduces the computational burden, there exists a substantial body of work demonstrating that it results
in biased estimates, even in the simpler case of univariate joint models [see Tsiatis and Davidian, 2004,
Rizopoulos, 2012, and references therein]. This bias is a result of not working with the full joint distribution,
which would produce estimates of θy and b that are appropriately corrected for informative dropout relating
to the occurrence of an event.
To overcome this issue, we propose the correction of the estimates we obtain from the two-stage approach
using importance sampling weights [Press et al., 2007, Section 7.9]. In particular, we consider that the
realizations {θ
(m)
t , θ
(m)
y , b
(m);m = 1, . . . ,M} that we have obtain using the two-stage approach can be
considered a weighted sample from the full posterior of the multivariate joint model with weights given by:
w(m) =
p(θ
(m)
t | T˜ , δ,θ
(m)
y , b
(m)) p(θ
(m)
y , b
(m) | y, T˜ , δ)
p(θ
(m)
t | T˜ , δ,θ
(m)
y , b
(m)) p(θ
(m)
y , b
(m) | y)
. (6)
The numerator in this expression is the posterior distribution of the multivariate joint model, and the
denominator, the corresponding posterior distributions from each of the two stages. As previously stated,
from (6) we observe that the difference between fitting the full joint model versus the two-stage approach
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comes from the second term in the numerator and denominator. By expanding these two terms we obtain
p(θ
(m)
y , b | y, T˜ , δ)
p(θ
(m)
y , b
(m) | y)
∝
∏
i p(yi | b
(m)
i ,θ
(m)
y ) p(T˜i, δi | b
(m)
i ,θ
(m)
y ) p(b
(m)
i | θ
(m)
y ) p(θ
(m)
y )∏
i p(yi | b
(m)
i ,θ
(m)
y ) p(b
(m)
i | θ
(m)
y ) p(θ
(m)
y )
=
∏
i
p(T˜i, δi | b
(m)
i ,θ
(m)
y )
=
∏
i
∫
p(T˜i, δi | b
(m)
i , θ
(m)
y ,θt) dθt. (7)
The resulting weights involve a marginal likelihood calculation, which we perform using a Laplace approxi-
mation, namely
̟(m) = exp
[ q log(2π)− log{det(Σ̂(m))}
2
+ log{p(T˜i, δi | b
(m)
i ,θ
(m)
y , θ̂
(m)
t )}
]
,
w˜(m) = ̟(m)
/ M∑
m=1
̟(m),
where
θ̂
(m)
t = argmax
θt
[
log{p(T˜i, δi | b
(m)
i ,θ
(m)
y , θ̂t)}
]
,
det(A) denotes the determinant of matrix A,
Σ̂(m) = −∂2 log{p(T˜i, δi | b
(m)
i ,θ
(m)
y , θ̂t)}
/
∂θ⊤t ∂θt
∣∣
θt=θˆ
(m)
t
,
and q denotes the dimensionality of the θt vector. The extra computational burden of performing this
Laplace approximation is minimal in practice, since good initial values can be provided from one iteration
m to the next m+ 1, which substantially reduces the number of required optimization iterations for finding
θ̂
(m)
t (i.e., θ̂
(m)
t is provided as an initial value to find θ̂
(m+1)
t ).
4.2 Performance
To evaluate whether the introduction of the importance sampling weights alleviates the bias observed with
the simple two-stage approach (i.e., without the weights), we perform a ‘proof-of-concept’ simulation study.
In particular, we compare the proposed corrected two stage approach with the simple two-stage approach,
as well as the full multivariate joint model in the case of two continuous longitudinal outcomes. The specific
details of this simulation setting are given in Appendix A.1. The results from 500 simulated datasets are
presented in Figure 1 and in the appendix, in Figures D.1 and D.2.
[Figure 1 about here.]
Figure D.1 shows boxplots with the computing times required to fit the joint model under three approaches.
Comparing the first two of these approaches, we see that the calculation of the importance-sampling weights
in the corrected two-stage approach had minimal computational cost, with the full multivariate joint model
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taking substantially more time to fit. Figure D.2 shows boxplots of posterior means from the 500 datasets for
the parameters of the two longitudinal submodels. We observe that all three approaches provide very similar
results with minimal bias. Figure 1 shows the corresponding boxplots of posterior means for the parameters
of the survival submodel. As expected, the full multivariate joint model returns unbiased results. Similarly,
as has previously been reported in the literature, the simple two-stage approach exhibits considerable bias.
We see that this bias persists for the corrected two-stage approach, although theoretically the use of the
importance sampling weights should alleviate it (by adjusting the posterior means obtained via the simple
two-stage approach such that they more closely resemble those from the full multivariate model).
5 Corrected Two-Stage Approach with Random Effects
5.1 Importance sampling correction with random effects
The above result is unexpected, since (as per Figure D.2), the corrected two-stage (and indeed the simple two-
stage) approach unbiasedly estimates both the fixed effects and the variance components of the longitudinal
submodels. However, further investigation shows that there is a considerable difference between the corrected
two-stage approach and the multivariate joint model with regards to the posterior of the random effects.
This is depicted in Figure 2 for one of the longitudinal outcomes we have simulated.
[Figure 2 about here.]
The data have been simulated such that higher values for longitudinal outcome y1 are associated with a
higher hazard of the event. From Figure 2 we observe that the random effect estimates for the multivariate
mixed model, and especially the random slope estimates for subjects with and without an event differ from
those for the multivariate joint model. In particular, we observe that the random slope estimates from the
joint model are larger for subjects with an event compared to the linear mixed model, and vice versa for
subjects without an event. This observation suggests that we could improve the weights given in (6) by
updating (in the second stage) not only the parameters of the survival submodel θt but also the random
effects b. That is, we obtain a sample for the parameters of the survival submodel {θ
(m)
t , b
(m);m = 1, . . . ,M}
from the corresponding joint posterior distribution,
p(θt, b | T˜ , δ,y,θ
(m)
y ) ∝
n∏
i=1
K∏
k=1
nki∏
j=1
p(ykij | bki,θ
(m)
y ) p(bki | θ
(m)
y ) p(T˜i, δi | θt, bi,θ
(m)
y ) p(θt). (8)
Admittedly, simulating from [θt, b | T˜ , δ,y, θ
(m)
y ] is more computationally intensive than simulating from [θt |
T˜ , δ, θ(m)y , b
(m)], the corresponding second stage presented in Section 4, since we now also need to calculate
the densities of the mixed-effect models for the K longitudinal outcomes. Nonetheless, the computational
gains compared to fitting the full joint model remain significant.
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Under this second stage (8) the importance sampling weights now take the form:
w(m) =
p(θ
(m)
t , b
(m) | T˜ , δ,θ(m)y ) p(θ
(m)
y | y, T˜ , δ)
p(θ
(m)
t , b
(m) | T˜ , δ,y,θ
(m)
y ) p(θ
(m)
y , b
(m) | y)
. (9)
Similarly to (6), the new weights have been formulated such that the difference lies in the second term in
both the numerator and denominator. By doing an expansion of these two terms similar to that used in the
previous section, we obtain:
w(m) =
p(θ
(m)
y | y, T˜ , δ)
p(θ
(m)
y , b
(m) | y)
∝ ̟(m) =
∏
i p(yi, T˜i, δi | θ
(m)
y ) p(θ
(m)
y )∏
i p(yi | b
(m)
i ,θ
(m)
y ) p(b
(m)
i | θ
(m)
y ) p(θ
(m)
y )
=
∏
i
∫ ∫
p(yi | bi, θ
(m)
y )p(T˜i, δi | bi,θ
(m)
y ,θt) p(bi | θ
(m)
y ) p(θt) dbidθt∏
i p(yi | b
(m)
i ,θ
(m)
y ) p(b
(m)
i | θ
(m)
y )
, (10)
and the self-normalized weights are
w˜(m) = ̟(m)/
∑
m
̟(m).
The integrals in the numerator are once again approximated using the Laplace method, namely, we let
{
θ̂
⊤
t , b̂
⊤
i
}⊤
= argmax
θt,bi
{∑
j
log p(yij | bi,θ
(m)
y ) + log p(T˜i, δi | bi,θ
(m)
y ,θt) + log p(bi | θ
(m)
y ) + log p(θt)
}
,
and
Σbi = −
∂2
{
log p(yi | bi,θ
(m)
y ) + log p(T˜i, δi | bi,θ
(m)
y , θ̂t) + log p(bi | θ
(m)
y )
}
∂b⊤∂b
∣∣∣
b=bˆi
,
denote the Hessian matrix for the random effects, and analogously,
Σθt = −
∂2
∑
i
{
log p(T˜i, δi | b̂i,θ
(m)
y ,θt) + log p(θt)
}
∂θ⊤t ∂θt
∣∣∣
θt=θˆt
,
denote the Hessian matrix for the θt parameters. Then, we approximate the inner integral by
p(yi, T˜i, δi | θ
(m)
y , θ̂t) ≈ exp
[
κ log(2π)− log
{
det(Σbi )
}
2
+ log p(yi | b̂i, θ
(m)
y ) + log p(T˜i, δi | b̂i,θ
(m)
y , θ̂t)+
log p(b̂i | θ
(m)
y )
]
,
where κ denotes the number of random effects for each subject i. Similarly, the outer integral is approximated
as
p(yi, T˜i, δi | θ
(m)
y ) ≈ exp
[
q log(2π)− log
{
det(Σθ)
}
2
+
∑
i
log p(yi, T˜i, δi | θ
(m)
y , θ̂t)
]
.
Given the requirement for a double Laplace approximation, and the fact that the denominator does not
simplify, the calculation of the ̟(m) weights given by (10) is more computationally intensive than the ones
presented in Section 4. Nevertheless, these required computations still remain many orders of magnitude
faster than fitting the full joint model.
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5.2 Performance
To assess whether updating the random effects in the importance sampling weights alleviates the bias we
observed in Section 4.2, we have re-analyzed the same simulated datasets. The details are again given
in Appendix A.1. The results from 500 simulated datasets are presented in Figures 3, D.1, and D.3. As
anticipated, the corrected two-stage approach with updated random effects added only a small computational
cost, with the full multivariate joint model still taking considerably more time to fit than either of the
corrected two-stage approaches (Figure D.1). The boxplots depicting the posterior means from the 500
datasets for the parameters of the longitudinal submodels once again demonstrate similar results for all
three approaches (Figure D.3). Figure 3 shows the posterior means for the parameters of the survival
submodel. We observe that the bias seen for the corrected two-stage approach is now eliminated, with the
posterior means from the approach with updated random effects closely approximating those from the full
multivariate joint model.
[Figure 3 about here.]
6 Extra Simulations
Further simulations were performed in order to assess the performance of the importance-sampling-corrected
two-stage approach with the updated random effects, in different scenarios. Details of these simulations are
given in Appendices A.2 and A.3.
6.1 Scenario II
Scenario II included 6 continuous longitudinal outcomes. Owing to the increased number of outcomes,
the full multivariate joint model was not run. Table 1 shows the bias for the parameters of the survival
submodel, together with the RMSE and coverage (based on the 2.5% and 97.5% credibility intervals for each
parameter). Table C.1 in the appendix shows the same information for the parameters of the 6 longitudinal
outcomes.
[Table 1 about here.]
6.2 Scenario III
Scenario III again included 6 longitudinal outcomes, now of varying types: 3 continuous and 3 binary. Table 2
demonstrates yet again the alleviation of the bias achieved by updating the random effects.
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[Table 2 about here.]
7 Analysis of the Bio-SHiFT Dataset
In this section, we present the analysis of data from the Bio-SHiFT cohort study. During a median follow-up
period of 2.4 years (IQR: 2.32 - 2.45), estimated using the reverse Kaplan-Meier methodology Shuster J.J
[1991], 66/254 (26%) patients experienced the primary event of interest (a composite event, consisting of
hospitalisation for heart failure, cardiac death, LVAD placement and heart transplantation). Biomarkers were
measured at inclusion and subsequently every 3 months until the end of follow-up. We focus on 6 biomarkers:
the glomerular marker Cystatin C (CysC), two tubular markers; urinary N-acetyl-beta-D-glucosaminidase
(NAG) and kidney-injury-molecule (KIM)-1, and the markers N-terminal propBNP (NT-proBNP), cardiac
troponin T (HsTNT), and C-reactive protein (CRP). The latter three markers are known to be related to
poor outcomes in CHF patients, and measure various aspects of heart failure pathophysiology (wall stress,
myocyte damage and inflammation respectively). All biomarkers were logarithmically transformed for further
analysis (log base 2) due to skewness.
For each of NT-probnp, HsTNT and CRP, we included natural cubic splines in both the fixed and random
effects parts of their longitudinal models, with differing numbers of knots per outcome (Figure D.4). Simple
linear models with random intercept and slope were used for CysC, NAG and KIM-1. Thus, for each of
CysC, NAG and KIM-1 (k = 1, 2, 3), we fit:
E{yki(t) | bki} = βk0 + bki0 + (βk1 + bki1)× time.
For the remaining outcomes (k = 4, 5, 6), we have:
E{yki(t) | bki} = (βk0 + bki0) +
∑
p
(βkp + bkip)Bkn(t, λp),
where Bkn(t;λp) denotes the B-spline basis matrix for a natural cubic spline of time with two internal
knots placed at the 25th and 75th percentiles of the follow up times for NT-probnp (p = 1, 2, 3), and one
internal knot placed at the 50th percentile of the follow up times for each of HsTNT and CRP (p = 1, 2).
Boundary knots were set at the 5th and 95th percentiles. We assume a multivariate normal distribution for
the random effects, bi = (b
T
1i,b
T
2i, . . . ,b
T
6i)
T ∼ MVN(0,D), where D is a 16 × 16 unstructured variance
covariance matrix. For the survival process, we included the baseline variables: (standardized) age, sex,
NYHA class (class III / IV vs. class I / II), use of diuretics, presence or absence of ischemic heart disease
(IHD), diabetes mellitus, (standardized) BMI, and the estimated glomerular filtration rate (eGFR) value.
We fit 3 joint models, using the global-local ridge-type shrinkage prior previously described in each
case. Model 1 included only the current underlying value of the longitudinal marker for each of the 6
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markers. Model 2 included the current value and slope for each marker, and model 3 included the integrated
longitudinal profile for each marker (AUC). We thus have:
Model 1: hi(t) = h0(t) exp
[
γ
⊤
wi(t) +
K∑
k=1
αkηki(t)
]
,
Model 2: hi(t) = h0(t) exp
[
γ
⊤
wi(t) +
K∑
k=1
α1kηki(t) +
K∑
k=1
α2kη
′
ki(t)
]
,
Model 3: hi(t) = h0(t) exp
[
γ
⊤
wi(t) +
K∑
k=1
αk
∫ t
0
ηki(s) ds
]
.
The parameter estimates and 95% credibility intervals for the event process are presented in Table 3. Hazard
ratios are presented per doubling of level, slope or AUC at any point in time.
[Table 3 about here.]
Following adjustment for covariates, the estimated association parameters in Model 1 indicate significant
associations between the risk of the composite event and the current underlying values of NT-proBNP and
CRP, such that there is a 1.86 fold increase in the risk of the composite event (95% CI: 1.45 to 2.37), per
doubling of NT-probnp level, and a 1.44 fold increase in the risk of the composite event (95% CI: 1.1 to
1.89), per doubling of CRP level. No significant associations were found for any of HsTNT, CysC, NAG or
KIM-1. Similarly, no significant associations were found for the current underlying values of CysC, NAG or
KIM-1 in Model 2, and nor were there any significant associations between the risk of the composite event
and the slopes of the 6 continuous markers.
Model 3 indicates a significant association for NT-proBNP, with a 1.47 fold increase in the risk of the
composite event (95% CI: 1.21 to 1.79) per doubling of the area under the NT-proBNP profile.
Since the parameter estimates for each of the longitudinal outcomes remained fairly constant across
models, to avoid repetition, the estimates and 95% credibility intervals are presented for one model only
(Table C.4).
In previous analyses of these same 6 markers, the current underlying value, instantaneous slope and area
under the curve of each marker were each assessed independently of one another. Van Boven et al., 2018
found significant associations in all cases for CRP, HsTNT and NT-proBNP, and Brankovic et al., 2018
found significant associations for the current underlying values and slopes of each of CysC, NAG and KIM-1,
and the area under the curves for CysC, and NAG.
Van Boven et al., 2018 provided an additional multivariate analysis for CRP, HsTNT and NT-proBNP,
wherein the predicted individual profiles for each marker were separately determined, and functions thereof
were simultaneously included in a single extended Cox model as time-varying covariates. Models therefore
included either the current underlying values, the instantaneous slopes or the area under the curves for all
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3 markers simultaneously. In that analysis, only CRP and NT- proBNP were found to be independently
predictive of the composite event, with significant associations for each of the current underlying values and
slopes of these markers. In the model for the area under the curves, only NT- proBNP was significant.
8 Discussion
In this paper, we presented a novel approach for fitting joint models which allows for the inclusion of
multivariate longitudinal outcomes with realistic computing times. We demonstrated once again, the bias
of the estimated parameters for the survival process characteristic of the standard two-stage approach, and
proposed the use of an importance-sampling corrected two-stage approach, with updated random effects, in
its place. Our approach was shown to be successful, producing satisfactory results in a number of simulation
scenarios: both survival and longitudinal estimates were unbiased, and computing times were reduced by
several orders of magnitude, compared to the full multivariate joint model. We were easily able to incorporate
multiple outcomes in the analysis of the Bio-SHiFT data, obtaining very similar results to those previously
noted for the CHF-related biomarkers (CRP, HsTNT and NT-proBNP). We did not find any significant
associations between any of the renal markers (CysC, NAG and KIM-1) and the risk of the composite event
in the multivariate analysis, indicating that their predictive value may not be independent of the CHF-related
markers. While the simulations included up to 6 multiple outcomes of varying types, it would be interesting
to confirm our results in even more complex settings, (perhaps incorporating competing risks such as those
present in the Bio-SHiFT study), and to try determine the limits of the methodology. A further topic for
research would be methods for increasing the speed of computation involved in fitting the multivariate mixed
model itself, so as to extend the number of outcomes even further.
The proposed importance-sampling corrected two-stage estimation approach is implemented in function
mvJointModelBayes() in the freely available package JMbayes (version 0.8-0) for the R programming lan-
guage (freely available from the Comprehensive R Archive Network at http://cran.r-project.org/package=JMbayes).
An example of how these functions should be used can be found in the appendices.
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Figure 1: Simulation results from 500 datasets comparing the two-stage approach and the importance-
sampling-corrected two-stage approach with the full joint model for continuous longitudinal outcomes. The
three panels show posterior means from the 500 datasets for the three coefficients in the survival submodel,
namely the coefficient for the baseline group variable and the association parameters for the two longitudinal
outcomes. The dashed horizontal line indicates the true value of the coefficients.
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simulated dataset for the first longitudinal outcome between a linear mixed model and a joint model. The
left column panels correspond to all subjects, the middle column to subjects without an event, and the right
column panel to subjects with an event.
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Figure 3: Simulation results from 500 datasets comparing the importance-sampling-corrected two-stage
approach and the corrected two-stage approach with random effects with the full joint model for continuous
longitudinal outcomes. The three panels show posterior means from the 500 datasets for the three coefficients
in the survival submodel, namely the coefficient for the baseline group variable and the association parameters
for the two longitudinal outcomes. The dashed horizontal line indicates the true value of the coefficients.
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Parameter Bias RMSE Coverage
Group -0.02 0.19 0.96
α1 -0.01 0.04 0.93
α2 0.01 0.04 0.93
α3 -0.01 0.16 0.95
α4 0.03 0.17 0.95
α5 0.03 0.05 0.83
α6 -0.02 0.04 0.88
Table 1: Simulation results for parameters of the survival submodel (Simulation II)
Parameter Bias RMSE Coverage
Group -0.01 0.91 0.97
α1 -0.01 0.04 1.00
α2 0.01 0.04 1.00
α3 0.00 0.43 0.90
α4 0.02 0.88 0.96
α5 0.02 0.04 1.00
α6 -0.01 0.05 0.99
Table 2: Simulation results for parameters of the survival submodel (Simulation III)
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Event Process
Model 1: Current value
HR (95% CI) HR* p-value
Age 1.01 (0.99 to 1.03) 1.00 0.242
Sex (Male vs. Female) 1 (0.77 to 1.31) 1.06 0.97
NYHA Class (III / IV vs. I / II) 1.47 (0.97 to 2.64) 2.52 0.134
Diuretics (Yes vs. No) 1.12 (0.79 to 2.74) 0.96 0.77
IHD (Yes vs. No) 1.06 (0.88 to 1.55) 0.95 0.696
eGFR 1.01 (1 to 1.02) 1.01 0.048
BMI 1.04 (0.99 to 1.1) 1.03 0.14
Diabetes Mellitus 1.08 (0.86 to 1.79) 0.93 0.638
αCRP 1.44 (1.1 to 1.89) 1.25 0.008
αHsTNT 1.32 (0.99 to 1.84) 1.35 0.078
αNT−proBNP 1.86 (1.45 to 2.37) 2.20 <0.0001
αCysC 1.04 (0.55 to 2.48) 0.90 0.966
αNAG 0.89 (0.51 to 1.38) 0.55 0.66
αKIM−1 0.96 (0.74 to 1.22) 1.21 0.768
Model 2: Current value and slope
HR (95% CI) HR* p-value
Age 1.01 (0.99 to 1.03) 1.00 0.162
Sex (Male vs. Female) 0.99 (0.66 to 1.34) 0.91 0.994
NYHA Class (III / IV vs. I / II) 1.61 (0.97 to 2.97) 1.53 0.104
Diuretics (Yes vs. No) 1.2 (0.79 to 4.64) 0.95 0.736
IHD (Yes vs. No) 1.06 (0.84 to 1.56) 1.36 0.750
eGFR 1.01 (1 to 1.02) 1.01 0.090
BMI 1.04 (0.98 to 1.1) 1.08 0.236
Diabetes Mellitus 1.08 (0.84 to 1.73) 1.03 0.676
αCRP value 1.52 (1.19 to 1.99) 1.38 0.002
αHsTNT value 1.37 (1 to 1.89) 1.08 0.048
αNT−proBNP value 1.9 (1.48 to 2.44) 1.61 <0.0001
αCysC value 1.05 (0.47 to 3.2) 0.92 0.996
αNAGvalue 0.74 (0.36 to 1.22) 1.04 0.292
αKIM−1 value 0.92 (0.69 to 1.18) 1.02 0.534
αCRP slope 0.95 (0.55 to 1.5) 0.91 0.878
αHsTNT slope 0.84 (0.24 to 1.91) 1.05 0.734
αNT−proBNP slope 1.02 (0.7 to 1.48) 0.87 0.926
αCysC slope 1.75 (0.19 to 356.56) 1.35 0.826
αNAGslope 1.03 (0.08 to 6.63) 0.84 0.946
αKIM−1 slope 2.37 (0.61 to 63.48) 0.93 0.460
Model 3: AUC
HR (95% CI) HR* p-value
Age 1 (0.98 to 1.03) 1.01 0.812
Sex 1.02 (0.83 to 1.38) 1.00 0.944
NYHA Class (III / IV vs. I / II) 1.8 (0.99 to 3.25) 1.83 0.080
Diuretics (Yes vs. No) 1.18 (0.83 to 3.72) 1.22 0.680
IHD (Yes vs. No) 1.04 (0.85 to 1.4) 1.21 0.742
eGFR 1.01 (1 to 1.02) 1.00 0.166
BMI 1.03 (0.98 to 1.08) 1.02 0.286
Diabetes Mellitus 1.11 (0.89 to 1.87) 0.99 0.564
αCRP 1.18 (0.99 to 1.43) 1.10 0.064
αHsTNT 1.2 (0.98 to 1.56) 1.06 0.082
αNT−proBNP 1.47 (1.21 to 1.79) 1.50 <0.0001
αCysC 1.13 (0.73 to 2.6) 1.38 0.704
αNAG 0.96 (0.63 to 1.34) 1.12 0.846
αKIM−1 1 (0.82 to 1.19) 1.01 0.960
Table 3: Parameter estimates and 95% credibility intervals under the joint modelling analysis for the Bio-
SHiFT data. Hazard ratios are presented per doubling of level, slope or AUC at any point in time. HR* is
the estimate after importance sampling.
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A Simulation Study Design
A.1 Scenario I
Scenario I simulates 500 patients with a maximum of 15 repeated measurements per patient. We included
K = 2 continuous longitudinal outcomes and one survival outcome. The k longitudinal outcomes each had
form:
yki(t) = ηki(t) + ǫki(t)
= βk0 + βk1 × time + βk2 × group + βk3 × interaction + bki0 + bki1 × time + ǫki(t),
with ǫki(t) ∼ N(0, σ
2
k) and bki = (bki0, bki1)
T , with bi = (b
T
1i,b
T
2i)
T ∼MVN(0,D). The variance-covariance
matrix D has general form:
D =


D1 · · · Delse
· · · D2 · · ·
· · ·
. . . · · ·
· · · Dk


, Dk =

 Dk11 Dk12
Dk21 Dk22


and for Scenario I:
D1 = D2 =

 0.68 −0.08
−0.08 0.28

 ,withDelse = 0.10
Time was simulated from a uniform distribution between 0 and 25. For the survival outcome, adjusting for
group allocation, we used:
hi(t) = h0(t) exp
[
γ0 + γ1 × group +
K∑
k=1
αkηki(t)
]
= h0(t) exp
[
γ0 + γ1 × group + α1η1i(t) + α2η2i(t)
]
.
The baseline risk was simulated from a Weibull distribution h0(t) = φt
φ−1, with φ = 1.65. For the simulation
of the censoring times, an exponential censoring distribution was selected, with mean µ = 15, such that the
censoring rate was between 60% and 70%. More details are presented in Table C.3.
A.2 Scenario II
Scenario II is an extension of Scenario I, such that we now haveK = 6 continuous longitudinal outcomes. We
again simulate 500 patients with a maximum of 15 repeated measurements per patient. The k longitudinal
20
outcomes each had form:
yki(t) = ηki(t) + ǫki(t)
= βk0 + βk1 × time + βk2 × group + βk3 × interaction + bki0 + bki1 × time + ǫki(t),
with ǫki(t) ∼ N(0, σ
2
k) and bki = (bki0, bki1)
T , with bi = (b
T
1i,b
T
2i, . . . ,b
T
6i)
T ∼MVN(0,D),
D1 = D2 =

0.97 0.78
0.07 0.032

 ,D3 = D4 =

 0.13 −0.009
−0.009 0.002

 ,
D5 = D6 =

0.56 0.05
0.05 0.03

 , andDelse = 0.00
Time was simulated from a uniform distribution between 0 and 25. For the survival outcome, adjusting
for group allocation as in Scenario I, we used:
hi(t) = h0(t) exp
[
γ1 × group +
K∑
k=1
αkηki(t)
]
.
The baseline risk was simulated using B-splines with knots specified apriori. An exponential censoring
distribution was used for the simulation of the censoring times, with mean µ = 15, such that the censoring
rate was between 60% and 70%. Further details are again available in Table C.3.
A.3 Scenario III
In Scenario III, we simulate 500 patients with a maximum of 15 repeated measurements per patient, including
3 continuous and 3 binary longitudinal outcomes, such that:
gk
[
E{yki(t) | bki}
]
= ηki(t)
= βk0 + βk1 × time + βk2 × group + βk3 × interaction + bki0 + bki1 × time,
where gk(·) denotes the canonical link function appropriate to the response type (identity and logit for the
gaussian and binomial outcomes respectively), and bi = (b
T
1i,b
T
2i, . . . ,b
T
6i)
T ∼MVN(0,D), with
D1 = D2 =

0.97 0.78
0.07 0.032

 ,D3 = D4 =

 0.13 −0.009
−0.009 0.002

 ,
D5 = D6 =

0.56 0.05
0.05 0.03

 , andDelse = 0.00
For the survival outcome, adjusting for group allocation, we again used:
hi(t) = h0(t) exp
[
γ1 × group +
K∑
k=1
αkηki(t)
]
.
Scenario III maintains the use of the uniform distribution between 0 and 25 for time, and the use of B-splines
for the simulation of the baseline hazard. The censoring times were simulated using an exponential censoring
distribution as before, with mean µ = 15. Table C.3 provides additional information.
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B Example R Code
The below code fits a multivariate joint model for K = 3 longitudinal outcomes: y1, y2 and y3, where y1 is
binary and both y2 and y3 are continuous. We fit a linear mixed model for y1 with random intercept and
slope (time is futime), and use natural cubic splines with two knots, (at futime = 6 and futime = 15
respectively) in both the fixed and random parts of the models for y2 and y3. The survival submodel adjusts
for continuous baseline predictors x1 and x2.
# LIBRARIES: JMbayes, splines, survival
# MULTIVARIATE MIXED MODEL
MixedModel <- mvglmer(list(y1 ~ futime + (futime | id),
y2 ~ ns(futime, knots = c(6, 15), Boundary.knots = c(0, 27)) +
(ns(futime, knots = c(6, 15), Boundary.knots = c(0, 27)) | id),
y3 ~ ns(futime, knots = c(6, 15), Boundary.knots = c(0, 27)) +
(ns(futime, knots = c(6, 15), Boundary.knots = c(0, 27)) | id)),
data = longit,
families = list(binomial, gaussian, gaussian))
# SURVIVAL SUB MODEL
SurvFit <- coxph(Surv(months, pe) ~ x1 + x2, data = surv, model = TRUE)
# MULTIVARIATE JOINT MODEL
JointFitAll <- mvJointModelBayes(MixedModel, SurvFit,timeVar = "futime")
summary(JointFitAll, TRUE)
# , TRUE is necessary to obtain the importance-sampling weighted estimates
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C Tables
Outcome Y1 Outcome Y2 Outcome Y3
Parameter Bias RMSE Coverage Bias RMSE Coverage Bias RMSE Coverage
Intercept 0.00001 0.06 0.96 0.00001 0.06 0.94 0.00000 0.02 0.96
Group 0.00000 0.09 0.95 0.00000 0.09 0.93 0.00000 0.03 0.95
Interaction -0.00001 0.02 0.92 0.00000 0.02 0.97 0.00000 0.00 0.96
Time 0.00001 0.01 0.95 0.00001 0.01 0.96 0.00000 0.00 0.96
Sigma 0.00000 0.00 0.95 0.00001 0.00 0.96 0.00000 0.00 0.96
Outcome Y4 Outcome Y5 Outcome Y6
Parameter Bias RMSE Coverage Bias RMSE Coverage Bias RMSE Coverage
Intercept -0.00001 0.02 0.96 -0.00001 0.06 0.95 -0.00001 0.07 0.94
Group 0.00001 0.03 0.95 0.00000 0.09 0.95 0.00001 0.09 0.94
Interaction 0.00001 0.00 0.95 0.00000 0.02 0.95 0.00001 0.02 0.95
Time 0.00001 0.00 0.96 0.00000 0.01 0.96 0.00001 0.01 0.95
Sigma 0.00000 0.00 0.94 0.00001 0.01 0.93 0.00000 0.01 0.94
Supplementary Table C.1: Simulation results for parameters of the longitudinal submodel (Simulation II)
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Outcome Y1 Outcome Y2 Outcome Y3
Parameter Bias RMSE Coverage Bias RMSE Coverage Bias RMSE Coverage
Intercept 0.00002 0.07 0.97 0.00001 0.07 0.97 -0.00001 0.05 0.93
Group 0.00000 0.11 0.95 -0.00001 0.11 0.96 0.00000 0.07 0.94
Interaction -0.00001 0.02 0.94 -0.00001 0.02 0.95 0.00000 0.01 0.93
Time 0.00002 0.01 0.95 0.00001 0.01 0.96 0.00001 0.01 0.93
Sigma -0.00001 0.01 0.95 0.00002 0.01 0.96 0.00000 0.01 0.94
Outcome Y4 Outcome Y5 Outcome Y6
Parameter Bias RMSE Coverage Bias RMSE Coverage Bias RMSE Coverage
Intercept -0.00002 0.10 0.94 0.00000 0.12 0.95 -0.00001 0.12 0.95
Group 0.00001 0.13 0.95 0.00000 0.15 0.97 -0.00001 0.15 0.96
Interaction 0.00002 0.02 0.93 0.00000 0.03 0.96 0.00001 0.03 0.96
Time 0.00001 0.02 0.93 -0.00002 0.03 0.94 0.00002 0.03 0.93
Supplementary Table C.2: Simulation results for parameters of the longitudinal submodel (Simulation III)
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Scenario Y αk βk = (βk0, βk1, βk2, βk3) σk γk = (γk0, γk1)
I
1 0.64
(2.13, -0.25, 0.24, -0.05) 0.6 (-5.8, 0.48)
2 -0.64
II
1 1.09
(0.73, 0.24, -0.30, -0.07) 0.34 (na, -0.2)
2 -1.09
3 -0.92
(5.75, 0.07, 0.04, 0.013) 0.19 (na, -0.2)
4 0.92
5 0.43
(10.97, 0.22, -0.42, 0.01) 1.06 (na, -0.2)
6 -0.43
III
1 0.17
(10.98, 0.21, -0.45, 0.05) 1.1 (na, -0.47)2 -0.17
3 0.17
4 -0.17
(1.11, 0.14, -1.09, 0.01) na (na, -0.47)5 0.47
6 -0.47
Supplementary Table C.3: Simulation Scenarios
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Longitudinal Process
CystatinC NAG KIM-1
Est. (95% CI) Est.* p-value Est. (95% CI) Est.* p-value Est. (95% CI) Est.* p-value
Intercept -0.36 (-0.42 to -0.31) -0.38 <0.0001 2.46 (2.34 to 2.58) 2.42 <0.0001 8.93 (8.78 to 9.07) 8.99 <0.0001
Time (years since baseline) -0.04 (-0.07 to -0.01) -0.05 0.004 -0.06 (-0.13 to 0) -0.07 0.058 0.01 (-0.05 to 0.08) 0.02 0.69
σ 0.43 (0.42 to 0.45) 0.43 <0.0001 0.93 (0.9 to 0.97) 0.93 <0.0001 0.85 (0.82 to 0.88) 0.81 <0.0001
CRP HsTNT NTS-proBNP
Est. (95% CI) Est.* p-value Est. (95% CI) Est.* p-value Est. (95% CI) Est.* p-value
Intercept 1.06 (0.87 to 1.26) 1.05 <0.0001 4.17 (4.02 to 4.32) 4.17 <0.0001 6.78 (6.54 to 7.01) 6.59 <0.0001
Bn(T ime, λ1) 0.96 (0.65 to 1.26) 1.18 <0.0001 0.17 (0.05 to 0.29) 0.26 0.01 0 (-0.17 to 0.18) 0.12 1.00
Bn(T ime, λ2) 0.5 (0.31 to 0.69) 0.35 <0.0001 0.17 (0.1 to 0.26) 0.17 <0.0001 -0.04 (-0.3 to 0.23) 0.05 0.75
Bn(T ime, λ3) na na na na na na 0.17 (0.03 to 0.34) 0.23 0.01
σ 1 (0.96 to 1.04) 0.99 <0.0001 0.28 (0.27 to 0.29) 0.29 <0.0001 0.5 (0.48 to 0.52) 0.5 <0.0001
Supplementary Table C.4: Parameter estimates and 95% credibility intervals under the joint modelling
analysis for the Bio-SHiFT data (Model 1). Est.* are the estimates after importance sampling.
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Supplementary Figure D.1: Simulation results from 500 datasets comparing the importance-sampling-
corrected two-stage approach with and without updated random effects with the full multivariate joint
model. The boxplots show the mean computational time per approach.
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Supplementary Figure D.2: Simulation results from 500 datasets comparing the simple two-stage approach
and the importance-sampling-corrected two-stage approach with the full multivariate joint model. The panels
show the posterior means from the 500 datasets for the coefficients from the two longitudinal outcomes in
Scenario I. The dashed horizontal line indicates the true value of the coefficients.
29
Po
st
er
io
r M
ea
ns
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
Outcome 1: Intercept
−
0.
6
−
0.
4
−
0.
2
0.
0
0.
2
Outcome 1: Group
0.
0
0.
1
0.
2
0.
3
0.
4
Outcome 1: Year
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
Outcome 1: Interaction
0.
0
0.
2
0.
4
0.
6
Outcome 1: Sigma
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
Corrected
2−Stage
Corrected
2−Stage
with RE
Multv.
JM
Outcome 2: Intercept
−
0.
6
−
0.
4
−
0.
2
0.
0
Corrected
2−Stage
Corrected
2−Stage
with RE
Multv.
JM
Outcome 2: Group
0.
0
0.
1
0.
2
0.
3
0.
4
Corrected
2−Stage
Corrected
2−Stage
with RE
Multv.
JM
Outcome 2: Year
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
Corrected
2−Stage
Corrected
2−Stage
with RE
Multv.
JM
Outcome 2: Interaction
0.
0
0.
2
0.
4
0.
6
Corrected
2−Stage
Corrected
2−Stage
with RE
Multv.
JM
Outcome 2: Sigma
Supplementary Figure D.3: Simulation results from 500 datasets comparing the importance-sampling-
corrected two-stage approach with and without updated random effects with the full multivariate joint
model. The panels show the posterior means from the 500 datasets for the coefficients from the two longi-
tudinal outcomes in Scenario I. The dashed horizontal line indicates the true value of the coefficients.
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Supplementary Figure D.4: Longitudinal profiles of continuous biomarkers (log base 2) for a randomly
selected subset of individuals from the Bio-SHiFT cohort study that did/did not experience the primary
event of interest.
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